Clot formation and fibrinolysis assays reveal functional differences among hemostatic agents in hemophilia A plasma
Open Access
- 5 February 2024
- journal article
- research article
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 8 (1) , 102337
Abstract
No abstract availableKeywords
Funding Information
- Takeda Pharmaceuticals America Inc
- National Institutes of Health
This publication has 57 references indexed in Scilit:
- The effect of a next generation factor VIII mimetic bispecific antibody (Mim8) on assays of factor VIII activity and thrombin generationJournal of Thrombosis and Haemostasis, 2023
- Tranexamic acid evidence and controversies: An illustrated reviewResearch and Practice in Thrombosis and Haemostasis, 2021
- The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editingThe Lancet, 2021
- Issues complicating precision dosing for factor VIII prophylaxisTransfusion and Apheresis Science, 2018
- Novel assays in the coagulation laboratory: a clinical and laboratory perspectiveTransfusion and Apheresis Science, 2018
- Clot stability as a determinant of effective factor VIII replacement in hemophilia AResearch and Practice in Thrombosis and Haemostasis, 2017
- Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasmaThrombosis Research, 2011
- What is all that thrombin for?Journal of Thrombosis and Haemostasis, 2003
- Platelet activity of high‐dose factor VIIa is independent of tissue factorBritish Journal of Haematology, 1997
- Pharmacokinetics and pharmacodynamics of recombinant factor VIIaClinical Pharmacology & Therapeutics, 1994